PharmaFocus Today – Page 18 – media

Sinovac’s trivalent influenza vaccine has been expanded to cover all age groups, including those 6 months and older.

According to Sinovac BiotechNews: On October 23, 2025, Beijing Sinovac Biotech Co., Ltd. produced a trivalent influenza vaccine.The National Medical Products Administration (NMPA) has approved the expanded age range for the Sinovac Biotech vaccine Anlelaifu® (0.5ml/dose), increasing the target population to include individuals aged 6-35 months and expanding the applicable population to all individuals aged 6 months and older. This month, Sinovac’s quadrivalent influenza vaccine (0.5ml/dose) and trivalent influenza vaccine (0.5ml/dose) have also received approval for expanded age ranges, meaning the company’s seasonal influenza vaccines now offer a unified dosage form for individuals aged 6 months and older. Source: https://finance.eastmoney.com/a/202510303549825713.html
- Source: drugdu
- 87
- October 30, 2025
Jiuzhitang plans to acquire and increase its investment in Jixianglong to enter the field of polypeptide raw materials.

Shanghai Securities News China SecuritiesOn the evening of October 29th, Jiuzhitang…The company announced that it plans to acquire a portion of the equity of Harbin Jixianglong Biotechnology Co., Ltd. for RMB 210 million and increase its capital in Jixianglong by RMB 100 million. After the aforementioned transactions are completed, Jiuzhitang will hold 51.6667% of the equity of Jixianglong, and Jixianglong will be included in its consolidated financial statements. It is understood that Jixianglong is a company specializing in peptide generic drug raw materials, peptide drug formulations, and innovative drugs.Jixianglong is a national high-tech enterprise specializing in R&D, production, and technical services, possessing core technologies and processes for the large-scale production of peptide APIs. Jixianglong currently holds 10 API production licenses, 1 formulation license, and 1 API pending approval; 8 of its products are included in national centralized procurement. It ranks third in China in the number of peptide API licenses, with atosiban and oxytocin being ...
- Source: drugdu
- 69
- October 30, 2025
“Rice-based blood production” attracts capital investment, boosting the market value of Heyuan Bio. What impact will this have on the blood products industry?

In the medical world, human serum albumin is hailed as a “golden life-saving drug.” It is the most widely used blood product, yet it remains trapped in traditional constraints—relying entirely on human plasma extraction. This not only leads to a perennial shortage of clinical supplies but also leaves the risk of viral transmission ever-present. Recently, Heyuan Bio, which just listed on the Science and Technology Innovation Board, is bringing with it “rice hematopoietic” technology, which is expected to break the limitations of traditional methods for preparing human serum albumin. The birth of Heyuan Biotechnology stems from a technological breakthrough by Professor Yang Daichang’s team at Wuhan University. In 2006, Yang Daichang founded Heyuan Biotechnology with his technological achievements. In July of this year, Heyuan Biotechnology’s core product HY1001 (Aofumin Recombinant Human Albumin Injection) was approved for marketing, becoming the first plant-derived recombinant human albumin drug in China. The capital market ...
- Source: drugdu
- 107
- October 30, 2025
US pharmaceutical giants find themselves in a passive position as the government ignores lobbying efforts and continues to ease approval requirements for generic drugs.

The U.S. government announced on Wednesday that it will expedite the approval process for complex biosimilars and relax the requirements for biosimilars developed using live cell technology, no longer requiring human trials as a prerequisite for developing biosimilars. This policy is expected to threaten some of the most profitable products in the U.S. pharmaceutical industry. Pharmaceutical industry leaders had previously lobbied intensely, spending millions of dollars to block the change, but ultimately failed. The U.S. Food and Drug Administration’s (FDA) move to expedite the approval of generic drugs is based on the recent agreement reached between U.S. President Trump and pharmaceutical companies to lower drug prices, which undoubtedly puts greater pressure on the pharmaceutical industry’s profits. So far this year, US pharmaceutical stocks have significantly underperformed the S&P 500 index, with Eli Lilly…PfizerCompanies like Merck have issued pessimistic outlooks due to uncertainty surrounding US policies, warning investors of potential profit risks. ...
- Source: drugdu
- 58
- October 30, 2025
FDA Announces New Biosimilar-Targeted Draft Guidance

FDA is taking aim at expensive biologic drugs. The agency announced new draft guidance to simplify biosimilarity studies and reduce clinical testing that it has deemed “unnecessary.”1 The goal of these moves, according to the agency, is to make it easier for pharmaceutical companies to develop biosimilars. What impact will FDA’s actions have on biosimilar development? FDA says that this will bring more low-cost alternatives to the market at a faster, more reliable rate. The new guidance is titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” In a press release, Health and Human Services Secretary Robert F. Kennedy Jr. said, “Today’s announcement of biosimilar reform furthers President Trump’s directive to lower drug prices for the American people. Biologics treat many chronic diseases, but for too long, a burdensome approval process has kept patients from accessing more affordable biosimilars. ...
- Source: drugdu
- 63
- October 30, 2025
Injectable Drug Helps Asthma Patients Clear Mucus-Clogged Airways

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 29, 2025 (HealthDay News) — An anti-inflammation injectable drug can reduce mucus buildup and improve breathing among asthma patients, a new clinical trial says. The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported Oct. 27 in the American Journal of Respiratory and Critical Care Medicine. Results found half as many patients had mucus-plugged airways following treatment with the drug. “In moderate-to-severe asthma, a buildup of mucus in the lungs can obstruct breathing airways to the point where affected patients suffer limited breathing, severe asthma attacks, and even death,” lead researcher Dr. Celeste Porsbjerg said in a news release. She’s a professor of severe asthma at Bispebjerg Hospital in Copenhagen, Denmark. Everyone has some mucus in their system, but it typically isn’t bothersome unless we’re stricken with a cold or the flu, researchers noted. But mucus can ...
- Source: drugdu
- 87
- October 30, 2025
Eli Lilly deploys the world’s largest AI-powered pharmaceutical factory, anticipating explosive growth.

According to reports, Eli LillyThe company has deployed the world’s largest and most powerful AI pharmaceutical factory, which uses NVIDIA- basedDGX supercluster based on Blackwell architecture. In terms of drug discovery, AI can identify potential drug targets and assist in drug molecule design by analyzing massive biomedical data. Using machine learning algorithms, AI can predict the structure, activity, and toxicity of compounds, quickly screen out candidate drugs with clinical potential, and shorten drug development time. According to TouBao Research Institute, from 2019 to 2023, the scale of China’s AI pharmaceutical market will increase from 70 million yuan to 410 million yuan, with a compound annual growth rate of 57.4%. It is estimated that from 2024 to 2028, the market size will increase from 730 million yuan to 5.86 billion yuan, with a compound annual growth rate of 68.5%. Soochow SecuritiesThe research report points out that the AI pharmaceutical industry is gradually entering a ...
- Source: drugdu
- 114
- October 29, 2025
Kangfang Biopharma’s new dual-antibody drug Ivoside is planned to be included in the breakthrough therapy designation for the treatment of triple-negative breast cancer

Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) On October 24, Kangfang Bio ‘s Class 1 new drug PD-1/VEGF dual antibody Ivoside (AK112) injection was planned to be included in the breakthrough therapy variety. The indication is Ivosidemab combined with chemotherapy as the first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer. Ivoside is a new dual-antibody drug with a synergistic anti-tumor mechanism of “tumor immunity + anti-angiogenesis.” It simultaneously targets two important targets, PD-1 and VEGF, and synergistically exerts both tumor immunity and tumor anti-angiogenesis mechanisms, potentially providing a more effective treatment option for these patients. In February 2025, Kangfang Bio announced that the first patient had been enrolled in the multicenter, randomized, double-blind Phase 3 clinical study (HARMONi-BC1/AK112-308) of Ivoside combination therapy as the first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Source：https://finance.eastmoney.com/a/202510243543410637.html
- Source: drugdu
- 83
- October 29, 2025
The KEX02 live bacteria capsule combined with PD-1 inhibitor for the treatment of non-small cell lung cancer is in Phase I clinical trials.

an investor asked on the investor interaction platform: Regarding the innovative　intestinal microecology drugs of the subsidiary Juntuo Biotechnology.What is the progress of the pipeline? What is the progress of the trial of combining PD-1 inhibitors for the treatment of non-small cell lung cancer? Ketuo BioOn October 24, 2019, the company (300858.SZ) announced on its investor engagement platform that it and Shenzhen Weizhijun Biotechnology Co., Ltd. are steadily advancing clinical research on their pipeline drug, KEX02 Live Bacteria Capsules, in combination with a PD-1 inhibitor for the treatment of non-small cell lung cancer. The project is currently in Phase I clinical trials. The company will disclose information promptly based on progress. Source：https://finance.eastmoney.com/a/202510243543555259.html
- Source: drugdu
- 75
- October 29, 2025
Zoletinib, a new generation TRK inhibitor, debuts on the international stage

Shanghai Securities News China SecuritiesNet News (Reporter Zhang Xue) The reporter learned from InnoCare Pharma that at the 2025 International Society of Pediatric Oncology (SIOP) Annual Meeting held recently, Professor Zhang Yizhuo, Director of the Department of Pediatric Oncology at the Cancer Prevention and Treatment Center of Sun Yat-sen University (as the main researcher), and team member Professor Wang Juan (representing a multi-center researcher) orally reported the Phase I/II clinical data of China’s independently developed new generation pan-TRK inhibitor zolecletinib in children and adolescents with advanced solid tumors, which attracted the attention of the global academic community. Studies have shown that zolecatinib exhibits controllable safety and good anti-tumor activity in children/adolescents with NTRK gene fusion-positive solid tumors, indicating that it is a potential treatment for NTRK gene-driven malignant tumors, especially in overcoming the resistance of first-generation TRK inhibitors, showing good effectiveness, bringing new treatment directions for this type of tumor. The report notes ...
- Source: drugdu
- 83
- October 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.